净收入和盈利 - 2024年第二季度，Enact的净收入为1.84亿美元，每股摊薄收益为1.16美元[4] - 调整后的营业收入为2.01亿美元，每股摊薄收益为1.27美元[4] 保险业务 - 主要保险在力量达到了2660亿美元，比2023年第二季度增长了3%[4] - PMIERs Sufficiency为169%，达到20.57亿美元[4] - 新保险签约额为140亿美元，较2024年第一季度增长29%[6] - 净保费收入为2.45亿美元，较2024年第一季度增长2%[6] 财务状况 - 现金及等价物加上投资资产为2.16亿美元和3.1亿美元[7] - 公司董事会批准了新的股票回购计划，授权回购高达2.5亿美元的普通股[8] 公司业绩 - 2024年第二季度，Enact Holdings, Inc.的总收入为298,834千美元，较去年同期增长了7.6%[18] - 2024年第二季度，Enact Holdings, Inc.的调整后营业收入为201,115千美元，较去年同期增长了12.7%[18] - 2024年第二季度，Enact Holdings, Inc.的基本每股调整后营业收入为1.28美元，较去年同期增长了15.3%[18] 资产和负债 - 2024年第二季度，Enact Holdings, Inc.的总资产为6,349,372千美元，较上一季度增长了0.7%[20] - 2024年第二季度，Enact Holdings, Inc.的股东权益为4,825,829千美元，较上一季度增长了2.4%[22] - 2024年第二季度，Enact Holdings, Inc.的每股净资产为30.91美元，较上一季度增长了3.4%[23] 财务指标 - 2024年第二季度，Enact Holdings, Inc.的调整后营业ROE为16.9%，较去年同期增长了2.7%[24] - 2024年第二季度，Enact Holdings, Inc.的资本负债比率为13%，较上一季度下降了1%[25]

GAAP Net Income of $184 million, or $1.16 per diluted shareAdjusted Operating Income of $201 million, or $1.27 per diluted shareReturn on Equity of 15.4% and Adjusted Operating Return on Equity of 16.9%Record Primary insurance in-force of $266 billion, a 3% increase from second quarter 2023PMIERs Sufficiency of 169% or $2,057 millionBook Value Per Share of $30.91 and Book Value Per Share excluding AOCI of $32.43Announces quarterly cash dividend of $0.185 per common share RALEIGH, N.C., July 31, 2024 (GLOBE ...

文章核心观点 - 公司开发了一种名为Iomab-ACT的靶向放射性疗法,用于治疗患有镰状细胞病的患者 [4][5] - Iomab-ACT可以在骨髓移植和基因疗法之前用作有针对性的预处理,减少化疗带来的严重毒性反应 [4][5] - 这种创新方法有望最大限度地减少毒性,同时确保完全的供体造血细胞植入 [5] - 这一试验有望为后续的基因疗法预处理研究提供信息,并为镰状细胞病患者提供更广泛的细胞疗法渠道 [4] 根据目录分别总结 公司概况 - 公司是一家开发靶向放射性疗法和其他靶向放射治疗的领导者 [9] - 公司拥有超过230项专利和专利申请,其中包括几项与在回旋加速器中制造Ac-225同位素相关的专利 [9] 产品管线 - 公司的主要产品候选药物包括Iomab-B(预BLA和MAA(欧盟))和Actimab-A(国家癌症研究所CRADA),这些药物已显示出延长复发和难治性急性髓系白血病患者生存期的潜力 [9] - 公司计划推进Iomab-B用于治疗其他血液肿瘤,并推进下一代预处理候选药物Iomab-ACT以改善细胞和基因疗法的结果 [9] 市场机会 - 靶向放射性预处理疗法的市场机会很大,因为所有接受细胞和基因疗法的患者都需要进行某种形式的预处理 [7] - 预计到2030年,美国的CAR-T和基因疗法的可治疗患者人群将近乎翻番,达到约93,000人 [7] - CAR-T疗法市场规模预计未来5年以上将以约11%的复合年增长率增长 [7] - 如果Iomab-ACT能够提供一种或多种临床获益,如降低细胞因子释放综合征(CRS)、减少免疫效应细胞相关神经毒性综合征(ICANS)、延长反应持续时间或提高细胞和基因疗法的整体成功率,那么它就有潜力成为一个潜在的重磅收入机会 [8]

tattywelshie/E+ via Getty Images One of the most eye-watering charts I've seen in a while is the one showing the rise in median prices of homes in the United States over the last ten years, recently touching nearly $435,000. As a parent of children not far off from being on their own, I can certainly sympathize with the frustrations of those who are priced out of the housing market, and I confess that I wonder about whether my children will be able to buy their own homes. Median home price, 2014 - 202 ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Enact Holdings, Inc. (ACT) , which belongs to the Zacks Insurance - Multi line industry, could be a great candidate to consider.This company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 6.97%.For the most recent quarter, ...

RALEIGH, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) announced it will issue its second quarter earnings release after the market closes on July 31, 2024. Enact will host a conference call to review second quarter 2024 financial results on August 1, 2024 at 8:00 a.m. (ET). Enact’s earnings release, summary presentation and financial supplement will be available through the company's website, https://ir.enactmi.com/, at the time of their release to the public. Participa ...

RALEIGH, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) announced it will issue its second quarter earnings release after the market closes on July 31, 2024. Enact will host a conference call to review second quarter 2024 financial results on August 1, 2024 at 8:00 a.m. (ET). Enact’s earnings release, summary presentation and financial supplement will be available through the company's website, https://ir.enactmi.com/, at the time of their release to the public. Participa ...

RALEIGH, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (NASDAQ:ACT) (Enact), a leading provider of private mortgage insurance through its insurance subsidiaries, today announced that its flagship legal entity, Enact Mortgage Insurance Corporation, has secured approximately $90 million of additional excess of loss (XOL) reinsurance coverage. This credit risk transfer (CRT) transaction covers a portion of existing mortgage insurance policies written from July 1, 2023 through December 31, 2023 a ...

RALEIGH, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact), a leading provider of private mortgage insurance through its insurance subsidiaries, today announced that its flagship legal entity, Enact Mortgage Insurance Corporation, has secured approximately $90 million of additional excess of loss (XOL) reinsurance coverage. This credit risk transfer (CRT) transaction covers a portion of existing mortgage insurance policies written from July 1, 2023 through December 31, 2023 ...

Wall Street’s popular adages are not matching this year. April is historically known as being favorable to investors. But this year, April ended on a disappointing note. For May, the popular adage is “Sell and Go Away.” However, May 2024 turned out highly successful for U.S. stock markets.The three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — were up 2.3%, 4.8% and 6.9%, respectively. The tech-heavy Nasdaq Composite recorded its best month since November 2023. On May 31, the blue-ch ...